This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Centogene Gestione

Gestione criteri di controllo 2/4

Centogene's Il CEO è Kim Stratton, nominato in Dec2021, e ha un mandato di 2.67 anni. la retribuzione annua totale è € 2.84M, composta da 24.1% di stipendio e 75.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.2% delle azioni della società, per un valore di € 47.16K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 5.8 anni.

Informazioni chiave

Kim Stratton

Amministratore delegato

€2.8m

Compenso totale

Percentuale dello stipendio del CEO	24.1%
Mandato del CEO	2.7yrs
Proprietà del CEO	1.2%
Durata media del management	2.5yrs
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Kim Stratton rispetto agli utili di Centogene?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	€3m	€684k	-€36m
Sep 30 2023	n/a	n/a	-€38m
Jun 30 2023	n/a	n/a	-€40m
Mar 31 2023	n/a	n/a	-€40m
Dec 31 2022	€2m	€861k	-€39m

Compensazione vs Mercato: La retribuzione totale di Kim ($USD 3.15M ) è superiore alla media delle aziende di dimensioni simili nel mercato German ($USD 538.74K ).

Compensazione vs guadagni: La retribuzione di Kim è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Kim Stratton (62 yo)

2.7yrs

Mandato

€2,843,000

Compensazione

Ms. Kim Stratton serves as Chief Executive Officer at Centogene N.V. since February 18, 2022 and serves as its Member of Management Board and served as its Interim Chief Executive Officer since December 20...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Kim Stratton	CEO & Member of Management Board	2.7yrs	€2.84m	1.2% € 56.2k
Jose Miguel Rios	CFO, Legal & IT and Member of Management Board	2.5yrs	€1.13m	0.48% € 22.5k
Peter Bauer	Interim MD	1.6yrs	€376.00k	0.079% € 3.7k
Andrin Oswald	Advisor	2.7yrs	€871.00k	Nessun dato
Ian Rentsch	Chief Commercial Officer & GM of Pharma	1.4yrs	Nessun dato	Nessun dato

2.5yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 39K è considerato esperto (durata media dell'incarico 2.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eric Souêtre	Independent Member of the Supervisory Board	7.6yrs	€20.00k	Nessun dato
Hubert Birner	Independent Member of the Supervisory Board	7.1yrs	€22.00k	Nessun dato
Peer Schatz	Independent Chairman of the Supervisory Board	4.4yrs	€717.00k	0.26% € 12.1k
Jonathan Sheldon	Independent Member of the Supervisory Board	3.7yrs	€97.00k	Nessun dato
Guido Prehn	Independent Member of the Supervisory Board	7.6yrs	€20.00k	Nessun dato
Mary Sheahan	Independent Member of the Supervisory Board	1.7yrs	€239.00k	Nessun dato

5.8yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 39K sono considerati esperti (durata media dell'incarico 5.8 anni).

This company listing is no longer active

Centogene Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Recent updates

Centogene Receives Delisting Notice from Nasdaq, Effective at the Open of Trading on August 8, 2024

Centogene Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

Centogene N.V. Provides Earnings Guidance for the Year 2024

Centogene Biodatabank Grows to Incorporate Disease Insights from over 850,000 Diverse Patients

Centogene N.V. announced delayed 20-F filing

New minor risk - Financial data availability

Centogene N.V. Provides Earnings Guidance for the Full Year 2023

Centogene N.V. Announces Changes to Supervisory Board

Centogene N.V.'s Frontotemporal Dementia Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

Centogene N.V. Announces the Discovery of A New Form of Early-Onset Dystonia and Parkinsonism

Centogene N.V. Expands Multiomic Diagnostic Portfolio with Newly-Launched Transcriptomic Offering

New major risk - Revenue and earnings growth

Centogene N.V. Reaffirms Revenue Guidance for the Year 2023

Centogene N.V. Announces Publication Establishing Lyso-Gb1 as A Predictive Biomarker for Gaucher Disease Patients

Centogene N.V. Announces Resignation of Berndt Modig from Supervisory Board

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort

Centogene N.V. announced that it expects to receive $30 million in funding from Lifera

New minor risk - Shareholder dilution

Centogene Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

Centogene N.V., Annual General Meeting, Jun 30, 2023

Centogene N.V., Annual General Meeting, Jun 30, 2023

Bettina Goerner Decides to Step Down as Chief Data Officer of Centogene N.V., Effective May 26, 2023

Full year 2022 earnings released: €1.45 loss per share (vs €2.09 loss in FY 2021)

Centogene N.V. Provides Revenue Guidance for Fiscal Year 2023

Centogene Regains Compliance with Nasdaq Listing Requirements

Centogene N.V. Appoints Prof. Peter Bauer, Chief Medical and Genomic Officer to its Management Board and as Managing Director of the subsidiary Centogene GmbH

Centogene N.V. Announces Resignation of Florian Vogel as Chief Process Officer, Effective February 28, 2023

Twist Bioscience and Centogene Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Second quarter 2022 earnings released: €0.44 loss per share (vs €0.37 loss in 2Q 2021)

Centogene N.V. Provides Revenue Guidance for the Fiscal Year 2022

Centogene Receives Nasdaq Non-Compliance Notice

Centogene N.V. Announces Changes to Supervisory Board

Centogene Launches Rare and Neurodegenerative Disease Biodata Network

First quarter 2022 earnings released: €0.49 loss per share (vs €0.22 loss in 1Q 2021)

Centogene N.V. Reaffirms Earnings Guidance for the Year 2022

Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director

Centogene N.V., Annual General Meeting, Jun 22, 2022

Centogene N.V., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings released: €2.09 loss per share (vs €1.02 loss in FY 2020)

Centogene N.V. Provides Earnings Guidance for the Year 2022

Centogene N.V. Appoints Miguel Coego Rios as Executive Vice President of Finance & Legal

Centogene N.V. announced that it has received €14.915363 million in funding from DPE Deutsche Private Equity GmbH, TVM Life Science Management Inc, Careventures S.A.

Centogene N.V. Announces the Global Release of CentoCloud, A SaaS Platform Enabling Decentralized Analysis, Interpretation, and Reporting of Genomic Variants Linked to Rare Diseases

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Centogene N.V. Provides Earnings Guidance for the Full Year 2021

Centogene N.V. Provides Revenue Guidance for the Second Half and Full Year of 2021

Second quarter 2021 earnings released

Chief Scientific Officer Philip Lambert has left the company

Executive Officer Richard Stoffelen has left the company

First quarter 2021 earnings released: €0.22 loss per share (vs €0.43 loss in 1Q 2020)

Centogene N.V. Announces Unaudited Consolidated Impairment Charges for the First Quarter Ended March 31, 2021

Centogene N.V. Initiates EFRONT Study to Identify Patients with Genetic Forms of Frontotemporal Dementia

Centogene N.V. Launches New CentoXome

Centogene N.V. Extends Global Parkinson’s Disease Study

Centogene N.V. Releases Centomd® 6.0 – the Company’s Rare Disease Database Powered by Its Bio/Databank

Centogene N.V. Discovers Six New Rare Diseases by Leveraging the Strength of its Bio/Databank

Full year 2020 earnings released: €1.02 loss per share (vs €1.27 loss in FY 2019)

Centogene Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study

New 90-day high: €10.60

Third quarter 2020 earnings released: €0.27 loss per share

Centogene N.V. to Report Q3, 2020 Results on Dec 16, 2020

Centogene Expands Express COVID-19 Antigen Testing to Frankfurt Airport

Centogene N.V. Expands Partnership with PTC Therapeutics, Inc. to Generate New Insights for Aromatic L-Amino Acid Decarboxylase Deficiency

New 90-day high: €11.85

Centogene N.V. Announces Partnership with U-Diagnostics B.V. to Provide Increased Covid-19 Testing to Communities Throughout the Netherlands

Centogene's Information Security Management System Awarded Iso/Iec 27001:2017 Accreditation

First half earnings released

New 90-day low: €8.26